CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
gamma-secretase/Notch signalling pathway inhibitor RO4929097drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01232829
NCT01232829Phase 2Completed
CompareCT.gov

A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

National Cancer Institute (NCI)·interventional·Posted Nov 2, 2010·Updated Nov 26, 2014

In Brief

A Phase 2 clinical trial evaluating gamma-secretase/Notch signalling pathway inhibitor RO4929097 for Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 18 participants across 3 sites.

Detailed Summary

This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2010
Enrollment StartOct 1, 2010
Primary CompletionJul 1, 2012
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.7 years ago

Interventions

gamma-secretase/Notch signalling pathway inhibitor RO4929097drug

Given PO